Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederbusinesswire.com
Business Wire - News by Company: AstraZeneca
Get the latest updates from Business Wire - News by Company: AstraZeneca directly as they happen.
Follow now 43 followers
Latest posts
Last updated 3 months ago
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies
3 months ago
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved...
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
4 months ago
WILMINGTON, Del.--(BUSINESS WIRE)--DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for...
CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma
4 months ago
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has...
Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
4 months ago
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab...
LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial
5 months ago
WILMINGTON, Del.--(BUSINESS WIRE)--Updated results from the OlympiA Phase III trial showed AstraZeneca...
Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
5 months ago
WILMINGTON, Del.--(BUSINESS WIRE)--Datopotamab deruxtecan (Dato-DXd) has been granted Breakthrough Therapy Designation (BTD)...
Fixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial
5 months ago
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the AMPLIFY Phase III trial showed AstraZeneca’s...
IMFINZI® (durvalumab) granted Priority Review in the US for patients with muscle-invasive bladder cancer
5 months ago
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has...
IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
5 months ago
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s IMFINZI® (durvalumab) has been approved in the US for...
TRUQAP® (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial
6 months ago
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the CAPItello-281 Phase III trial showed...
AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US
6 months ago
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today pledged $3.5 million to nonprofit organizations across the...
TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps
6 months ago
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the Phase III WAYPOINT trial in...